Pacira BioSciences Inc. (PCRX)
NASDAQ: PCRX
· Real-Time Price · USD
25.83
-0.10 (-0.39%)
At close: May 30, 2025, 3:59 PM
25.75
-0.31%
After-hours: May 30, 2025, 05:04 PM EDT
Pacira BioSciences Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Bupivacaine Liposome Injectable Suspension Revenue | 7.32M | 3.34M | 6.48M | 3.61M | 426.61M | 331.11M |
| Bupivacaine Liposome Injectable Suspension Revenue Growth | +119.09% | -48.39% | +79.59% | -99.15% | +28.84% | n/a |
| EXPAREL Revenue | 548.96M | 538.12M | 536.9M | 506.51M | n/a | n/a |
| EXPAREL Revenue Growth | +2.01% | +0.23% | +6.00% | n/a | n/a | n/a |
| Product Revenue | 697.19M | 672.25M | 664.15M | 12.68M | n/a | n/a |
| Product Revenue Growth | +3.71% | +1.22% | +5136.54% | n/a | n/a | n/a |
| ZILRETTA Revenue | 118.09M | 111.1M | 105.52M | n/a | n/a | n/a |
| ZILRETTA Revenue Growth | +6.29% | +5.29% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 86.78M | 79.61M | 74.33M | 68.13M | 72.03M | 65.8M | 67.95M | 64.85M | 70.84M | 63.97M | 61.28M | 65M | 64.26M | 52.15M | 48.81M | 50.81M | 48.52M | 52.83M | 52.56M | 43.34M | 44.78M | 54.22M | 50.13M | 49.13M | 48.52M | 44.65M | 44.18M | 44.25M | 44.19M | 39.18M | 40.64M | 39.55M | 42.12M | 34.67M | 36.31M | 43.67M | 37.96M | 37.55M | 35.31M | 34.75M | 31.43M |
| Selling, General, and Administrative Revenue Growth | +9.00% | +7.10% | +9.11% | -5.41% | +9.46% | -3.16% | +4.78% | -8.46% | +10.74% | +4.38% | -5.72% | +1.16% | +23.21% | +6.86% | -3.95% | +4.72% | -8.16% | +0.51% | +21.27% | -3.21% | -17.42% | +8.17% | +2.04% | +1.25% | +8.67% | +1.06% | -0.16% | +0.13% | +12.80% | -3.61% | +2.76% | -6.10% | +21.48% | -4.52% | -16.84% | +15.05% | +1.08% | +6.35% | +1.61% | +10.58% | n/a |
| Research and Development Revenue | 25.34M | 23.9M | 19.1M | 20.34M | 18.24M | 19.46M | 20.83M | 18.82M | 17.14M | 17.5M | 19.41M | 26.28M | 21.61M | 15.51M | 11.58M | 12.57M | 15.88M | 15.33M | 14.65M | 13.62M | 15.82M | 19.65M | 20.25M | 17.83M | 14.38M | 14.17M | 14.9M | 12.24M | 14.38M | 10.03M | 11.78M | 18.86M | 16.63M | 17.07M | 9.75M | 9.36M | 9.49M | 13.15M | 5.89M | 3.65M | 5.97M |
| Research and Development Revenue Growth | +6.05% | +25.09% | -6.07% | +11.51% | -6.29% | -6.56% | +10.66% | +9.82% | -2.09% | -9.79% | -26.17% | +21.65% | +39.26% | +34.00% | -7.91% | -20.82% | +3.57% | +4.64% | +7.57% | -13.90% | -19.51% | -2.97% | +13.62% | +23.94% | +1.48% | -4.85% | +21.72% | -14.88% | +43.38% | -14.84% | -37.55% | +13.37% | -2.56% | +74.99% | +4.19% | -1.38% | -27.83% | +123.20% | +61.50% | -38.85% | n/a |
| Sales and Marketing Revenue | 55.57M | 50.34M | 43.19M | 39.05M | 39.44M | 35.74M | 38.26M | 37.46M | 41.58M | 36M | 33.71M | 36.85M | 38.44M | 29.36M | 26.3M | 28.26M | 27.1M | 32.2M | 33.22M | 25.36M | 27.91M | 33.88M | 31.91M | 32.31M | 31.56M | 27.51M | 27.35M | 27.12M | 25.12M | 22.46M | 24.56M | 22.61M | 25.18M | 19.78M | 21.49M | 27.61M | 20.34M | 22.04M | 18.17M | 19.52M | 18.01M |
| Sales and Marketing Revenue Growth | +10.39% | +16.56% | +10.61% | -0.98% | +10.34% | -6.59% | +2.13% | -9.90% | +15.51% | +6.79% | -8.54% | -4.13% | +30.92% | +11.65% | -6.94% | +4.27% | -15.83% | -3.06% | +30.99% | -9.16% | -17.62% | +6.17% | -1.23% | +2.40% | +14.70% | +0.57% | +0.87% | +7.94% | +11.86% | -8.54% | +8.60% | -10.18% | +27.27% | -7.95% | -22.16% | +35.74% | -7.72% | +21.29% | -6.91% | +8.39% | n/a |